CXCR5 and hematologic disorder: As known, tumor-promoting functions and malignant B cells rescue of Tfh cells were discovered in hematological malignancies [31], and CXCR5 CAR-T cells targeting Tfh cells improved the therapeutic effect of immunotherapy in B cell non-Hodgkin's lymphoma (B-NHLs) [13].